Ginna G Laport

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Changing role of stem cell transplantation in follicular lymphoma
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305 5623, USA
    Hematology Am Soc Hematol Educ Program 2012:417-25. 2012
  2. pmc Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University School of Medicine, 300 Pastaur Drive, Stanford, CA 94305, USA
    Biol Blood Marrow Transplant 17:1679-87. 2011
  3. doi request reprint Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy
    Ginna G Laport
    Division of Blood and MarrowTransplantation, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305 5623, USA
    Curr Opin Oncol 22:409-13. 2010
  4. doi request reprint Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305 5623, USA
    Leuk Lymphoma 49:1854-9. 2008
  5. pmc Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Blood 112:903-9. 2008
  6. pmc Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
    Ginna G Laport
    Stanford University Medical Center, Stanford, California 94305 5623, USA
    Biol Blood Marrow Transplant 14:246-55. 2008
  7. ncbi request reprint The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, CA 94305, USA
    Biol Blood Marrow Transplant 12:59-65. 2006
  8. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for acute leukemia
    Ginna G Laport
    Division of Bone Marrow Transplantation, Stanford University Medical Center, 300 Pasteur Drive, Room H3249, Stanford, CA 94305 5623, USA
    Curr Hematol Rep 2:49-56. 2003
  9. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
  10. ncbi request reprint Protective conditioning for acute graft-versus-host disease
    Robert Lowsky
    Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1321-31. 2005

Detail Information

Publications19

  1. doi request reprint Changing role of stem cell transplantation in follicular lymphoma
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305 5623, USA
    Hematology Am Soc Hematol Educ Program 2012:417-25. 2012
    ..However, the outcomes seen after auto-HSCT and allo-HSCT continue to improve, and HSCT represents a treatment modality that should be considered in all FL patients, especially while their disease remains chemoresponsive...
  2. pmc Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University School of Medicine, 300 Pastaur Drive, Stanford, CA 94305, USA
    Biol Blood Marrow Transplant 17:1679-87. 2011
    ....
  3. doi request reprint Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy
    Ginna G Laport
    Division of Blood and MarrowTransplantation, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305 5623, USA
    Curr Opin Oncol 22:409-13. 2010
    ..The impact of high-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) as early consolidation therapy will be the focus of this review...
  4. doi request reprint Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305 5623, USA
    Leuk Lymphoma 49:1854-9. 2008
    ..Donor leukocyte infusions has been reported to induce durable remissions in relapsed HL patients even in patients who did not receive prior cytoreductive therapy which thus lends support to a graft versus HL effect...
  5. pmc Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Blood 112:903-9. 2008
    ..Our results indicate that FTBI/VP16 with or without cyclophosphamide confers long-term survival in Ph(+) ALL patients and that disease status at the time of HCT is an important predictor of outcome...
  6. pmc Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
    Ginna G Laport
    Stanford University Medical Center, Stanford, California 94305 5623, USA
    Biol Blood Marrow Transplant 14:246-55. 2008
    ..Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure...
  7. ncbi request reprint The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, CA 94305, USA
    Biol Blood Marrow Transplant 12:59-65. 2006
    ..This review summarizes current and new developments regarding the role of HCT for patients with follicular lymphoma...
  8. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for acute leukemia
    Ginna G Laport
    Division of Bone Marrow Transplantation, Stanford University Medical Center, 300 Pasteur Drive, Room H3249, Stanford, CA 94305 5623, USA
    Curr Hematol Rep 2:49-56. 2003
    ..This review discusses the background and rationale behind NMSCT and its impact on the treatment of patients with acute leukemia...
  9. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
    ..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
  10. ncbi request reprint Protective conditioning for acute graft-versus-host disease
    Robert Lowsky
    Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1321-31. 2005
    ..Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans...
  11. ncbi request reprint CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Exp Hematol 33:279-85. 2005
    ..G-PBMC cell contents were analyzed for influence on outcomes...
  12. pmc Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma
    Sally Arai
    Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:1145-54. 2010
    ..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
  13. ncbi request reprint Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Schol of Medicine, 300 Pasteur Dr, H3249, MC 5623, Stanford, CA 94305 5623, USA
    Blood 105:2300-6. 2005
    ..003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for reduced-intensity allografting may adversely affect T-cell engraftment and survival outcome...
  14. pmc TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
    Holbrook E Kohrt
    Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    Blood 114:1099-109. 2009
    ..Active trial registration currently at clinicaltrials.gov under IDs of NCT00185640 and NCT00186615...
  15. pmc Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
    Sally Arai
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305, USA
    Blood 119:6145-54. 2012
    ..01). Overall survival and freedom from progression at 4 years for chronic lymphocytic leukemia patients were 73% and 47%, respectively; for mantle-cell lymphoma patients, they were 69% and 53%, respectively...
  16. pmc Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience
    Andy I Chen
    Stanford University Medical Center, Division of Blood and Marrow Transplantation, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 14:741-7. 2008
    ....
  17. ncbi request reprint Mantle cell lymphoma in first complete remission
    Ginna G Laport
    Stanford University Medical Center, CA, USA
    Biol Blood Marrow Transplant 13:1118-9. 2007
  18. ncbi request reprint Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
    Ginna G Laport
    Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Blood 102:2004-13. 2003
    ....
  19. ncbi request reprint Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation
    Partow Kebriaei
    Department of Medicine and Cancer Research Center, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Leuk Res 28:537-40. 2004
    ..The emergence of clonal hematopoiesis may provide insights into therapy-related leukemogenesis...